Tolvaptan for the Treatment of Refractory Ascites.
作者信息
Kurosaki Masayuki, Izumi Namiki
机构信息
Department of Gastroenterology and Hepatology, Musashino Red Cross Hospital, Japan.
出版信息
Intern Med. 2016;55(20):2909-2910. doi: 10.2169/internalmedicine.55.7556. Epub 2016 Oct 15.
Abstract
摘要
相似文献
1
Tolvaptan for the Treatment of Refractory Ascites.托伐普坦用于治疗顽固性腹水
Intern Med. 2016;55(20):2909-2910. doi: 10.2169/internalmedicine.55.7556. Epub 2016 Oct 15.
2
Re-response to tolvaptan after furosemide dose reduction in a patient with refractory ascites.在一名难治性腹水患者中，呋塞米剂量减少后对托伐普坦的再次反应。
Clin J Gastroenterol. 2015 Feb;8(1):47-51. doi: 10.1007/s12328-014-0545-8. Epub 2014 Dec 5.
3
Survival Benefit of Tolvaptan for Refractory Ascites in Patients with Advanced Cirrhosis.托伐普坦对晚期肝硬化患者难治性腹水的生存获益
Dig Dis. 2018;36(4):314-321. doi: 10.1159/000489258. Epub 2018 May 31.
4
Cases with Refractory Ascites and a Delayed Response to Tolvaptan.顽固性腹水且对托伐普坦反应延迟的病例
Intern Med. 2016;55(22):3273-3277. doi: 10.2169/internalmedicine.55.7035. Epub 2016 Nov 15.
5
Tolvaptan for the treatment of liver cirrhosis oedema.托伐普坦用于治疗肝硬化水肿。
Expert Rev Gastroenterol Hepatol. 2014 Jul;8(5):461-70. doi: 10.1586/17474124.2014.903797. Epub 2014 Mar 29.
6
Predictive factors of the pharmacological action of tolvaptan in patients with liver cirrhosis: a post hoc analysis.托伐普坦在肝硬化患者中药理作用的预测因素：一项事后分析
J Gastroenterol. 2017 Feb;52(2):229-236. doi: 10.1007/s00535-016-1233-x. Epub 2016 Jul 5.
7
Tolvaptan in Chinese cirrhotic patients with ascites: A randomized, placebo-controlled phase 2 trial.托伐普坦治疗中国肝硬化腹水患者的随机、安慰剂对照 2 期临床试验。
J Dig Dis. 2018 Mar;19(3):144-154. doi: 10.1111/1751-2980.12583.
8
Curative Effect and Safety of Tolvaptan Combined With Traditional Diuretics in Treatment of Patients With Cirrhotic Ascites and Relevant Research on Its Dose.
Am J Ther. 2023;30(2):158-162. doi: 10.1097/MJT.0000000000001327. Epub 2021 Jan 1.
9
[Effect of tolvaptan on ascites due to malignancy].托伐普坦对恶性肿瘤所致腹水的影响
Gan To Kagaku Ryoho. 2015 Feb;42(2):201-5.
10
Urinary excretion of the water channel aquaporin 2 correlated with the pharmacological effect of tolvaptan in cirrhotic patients with ascites.尿水通道蛋白 2 排泄与托伐普坦在肝硬化腹水患者中的药效相关。
J Gastroenterol. 2016 Jun;51(6):620-7. doi: 10.1007/s00535-015-1143-3. Epub 2015 Nov 26.
引用本文的文献
1
Tolvaptan is effective in treating patients with refractory ascites due to cirrhosis.托伐普坦对治疗肝硬化所致难治性腹水患者有效。
Biomed Rep. 2017 Dec;7(6):558-562. doi: 10.3892/br.2017.1005. Epub 2017 Oct 23.
本文引用的文献
1
Predictors of the Effect of Tolvaptan on the Prognosis of Cirrhosis.托伐普坦对肝硬化预后影响的预测因素
Intern Med. 2016;55(20):2911-2916. doi: 10.2169/internalmedicine.55.6819. Epub 2016 Oct 15.
2
Urinary excretion of the water channel aquaporin 2 correlated with the pharmacological effect of tolvaptan in cirrhotic patients with ascites.尿水通道蛋白 2 排泄与托伐普坦在肝硬化腹水患者中的药效相关。
J Gastroenterol. 2016 Jun;51(6):620-7. doi: 10.1007/s00535-015-1143-3. Epub 2015 Nov 26.
3
Efficacy of tolvaptan in patients with refractory ascites in a clinical setting.托伐普坦在临床环境中对顽固性腹水患者的疗效。
World J Hepatol. 2015 Jun 28;7(12):1685-93. doi: 10.4254/wjh.v7.i12.1685.
4
Safety and efficacy of long-term tolvaptan therapy for decompensated liver cirrhosis.长期使用托伐普坦治疗失代偿期肝硬化的安全性和有效性。
Hepatol Res. 2016 Mar;46(3):E194-200. doi: 10.1111/hepr.12547. Epub 2015 Jul 23.
5
The treatment of vasopressin V2-receptor antagonists in cirrhosis patients with ascites: a meta-analysis of randomized controlled trials.血管加压素V2受体拮抗剂治疗肝硬化腹水患者：一项随机对照试验的荟萃分析。
BMC Gastroenterol. 2015 Jun 9;15:65. doi: 10.1186/s12876-015-0297-z.
6
Therapeutic effects of short- and intermediate-term tolvaptan administration for refractory ascites in patients with advanced liver cirrhosis.短期和中期使用托伐普坦治疗晚期肝硬化患者难治性腹水的疗效。
Hepatol Res. 2015 Nov;45(11):1062-70. doi: 10.1111/hepr.12455. Epub 2015 Jan 6.
Zotero 插件